Phase 2/3 Oxabact Study

计划入组 36 人 · 首次发布于 2009 年 12 月 22 日

ACE Pilot 3: Decision Aid 2 Options vs 3 Options

计划入组 100 人 · 首次发布于 2025 年 6 月 8 日

Ovulation Triggering 2 Vs 3 Follicles

计划入组 405 人 · 首次发布于 2024 年 3 月 4 日

HDAC1 inhibitors (Merck)

dual HDAC1/6 inhibitors (leukemia)

ERAS-2/3

3-D Matrix Ltd.

Japan

River 3 Renal Corp.

United States

Immuno Cure 3 Limited

Anbogen Receives FDA Clearance for Phase 1/2 Trial of ABT-301 Triplet Therapy in Metastatic Colorectal Cancer

HDAC inhibition turns cancer-cell quiescence into a druggable vulnerability against chemotherapy-resistant ovarian cancer

HDAC Inhibitors Market Projected to Surge Through 2034 as Next-Generation Cancer Therapies Advance in Clinical Trials